Introducing On/Go, our FDA-authorized at-home rapid COVID-19 self-test

October 18, 2021

Intrivo launches On/Go, an FDA authorized at-home rapid COVID-19 self-test, delivering results in just 10 minutes through unique AI-powered mobile app 

On/Go is a reliable, portable and affordable over-the-counter COVID-19 testing and tracing solution capable of detecting all known COVID-19 variants

Easy-to-use iOS and Android mobile apps guide users through an intuitive testing experience

Intrivo was awarded a U.S. Department of Defense contract to distribute On/Go to more than 25,000 locations across the U.S. that are among the most vulnerable populations

For population managers, Intrivo’s new AI-powered platform seamlessly integrates with On/Go rapid tests, offering a real-time solution to avoid costly shutdowns through rapid, targeted interventions that enable peace of mind

Manufactured in the U.S., Intrivo has the ability to ship tens of millions of tests monthly and hundreds of millions of tests yearly, and is continuing to ramp up production rapidly

Tests are available for direct rapid delivery at, Amazon, and

Miami, FL (October 19th, 2021) – Intrivo, a U.S.-based health-tech leader, announced today the launch of On/Go™, an at-home rapid COVID-19 antigen self-test that delivers results in just 10 minutes. On/Go, which has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), is an affordable and easy-to-use self-test with a companion app that guides users step-by-step through testing that is highly accurate, fast and convenient. In addition to direct-to-consumer and enterprise sales, Intrivo was also awarded a U.S. Department of Defense contract to distribute tens of millions of On/Go tests to 25,000 locations across the U.S. that are among the most vulnerable populations in need of rapid testing solutions. These locations include nursing homes, homeless shelters, National Guard sites, military bases and community testing sites. For population managers, On/Go offers an AI-powered platform that uses Intrivo’s proprietary technology to provide fast, accurate and actionable results in the first end-to-end testing-to-tracing COVID-control solution. The On/Go companion app is available now for free on iOS and Android, and allows for easy viewing, tracking, and sharing of test results. In response to high demand and current shortages of antigen tests, On/Go is readily available for both consumers and enterprises, and Intrivo is ramping up its U.S.-based production rapidly with tests available for order now. Made in the U.S., On/Go is available for delivery at, Amazon, and

“Given the widespread COVID-19 testing shortages, it’s more important than ever that we’re providing a holistic testing-to-tracing solution that’s highly reliable, quick, affordable, and easy to use,” said Reeve Benaron, founder and Co-CEO of Intrivo. “As a parent, businessman, and huge sports fan, I understand how COVID-19 has disrupted all aspects of daily life. We’re excited to provide a trusted and accessible solution that will help contain this pandemic and help our loved ones and communities get back to living their lives to the fullest.”

The test is as simple as “tap, swab, snap.” Users tap to start the app, gently swab their lower nostril, and take a quick snapshot of the test cassette with their phone camera. They are quickly provided personalized guidance and support based on their results. The On/Go app includes a unique, secure digital passport that includes current test results, and vaccine records, that can be used to gain access to restaurants, businesses, live events, travel and more. On/Go leverages individual test results to power population level insights in real time. Whether used by a large employer, business, hospital, entertainment venue, government entity, school or university, On/Go enables organizations of all types to stay ahead of COVID-19 and reduce costly shutdowns.

“Despite initial hopes, it’s clear that neither vaccines alone nor current diagnostics solutions can solve the COVID-19 crisis,'' said Ron Gutman, Co-CEO of Intrivo. “We are humbled by the rapid early adoption of our test+tech solutions, from the robust demand by Fortune 500 corporations, to becoming an Amazon best seller in our pre-launch tests, all the way to the opportunity to serve millions of vulnerable and under-served populations via Government partnerships. To make our new platform readily available for population managers, we also offer an attractive new business model called DaaS (Diagnostics as a Service). Intrivo’s DaaS package makes it easier to automatically administer tests directly, effortlessly identify and track pandemic outbreaks, and seamlessly manage them in real-time with highly targeted and personalized interventions. Thanks to the tireless commitment of our world-class team of scientists and technology leaders, we’re ready to disrupt COVID-19 for good. Together, the On/Go test and companion app are helping individuals and organizations everywhere get back to doing the things they love immediately, confidently, and cost-effectively.”

On/Go, powered by Intrivo, delivers a groundbreaking data-driven population management platform for targeted interventions that enables safer, happier, healthier lives for people everywhere. Order your On/Go tests today and download the app at

You might also like